ISIntira Sriprasert

Intira Sriprasert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Intira Sriprasert has a total of 118 co-authors. Here are the top co-authors by number of shared publications:

  • Donna Shoupe

    7 shared publications
  • Roksana Karim

    Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California

    6 shared publications
  • Frank Z. Stanczyk

    Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California

    4 shared publications
  • Howard N. Hodis

    Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California

    4 shared publications
  • Naoko Kono

    Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California

    4 shared publications
  • Wendy J. Mack

    Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California

    4 shared publications

Latest Publications

  • Initiation and Duration of Systemic Hormone Therapy for Menopausal Symptoms

    by Intira Sriprasert, Yongmei Huang, Donna Shoupe, Megan L. Evans, Xiao Xu, Jason D. Wright

    OBJECTIVE: To examine real-world patterns of systemic hormone therapy (HT) initiation and continuation among women with a diagnosis of menopause. METHODS: Using the Merative™ MarketScan® Research Databases (2009–2022), we identified women aged 45–60 years with menopause-related claims and at least 12 months of continuous enrollment. Patients with bilateral oophorectomy, breast or gynecologic cancers, or HT contraindications were excluded. Multivariable regression analyzed factors associated with HT initiation, formulation, and duration. RESULTS: Of 318,621 eligible women, 21.7% initiated systemic HT within 1 year. Predictors of HT initiation included younger age (adjusted odds ratio [aOR] 2.17; 95% CI, 2.12–2.23), prior hysterectomy (aOR 1.98; 95% CI, 1.77–2.21), and local hormone use (aOR 3.25; 95% CI, 3.05–3.47). Initiation was significantly lower among women with obesity (aOR 0.78; 95% CI, 0.75–0.81), diabetes (aOR 0.69; 95% CI, 0.66–0.72), and Black racial identification (aOR 0.78; 95% CI, 0.68–0.89). Initial formulations were estrogen plus progestogen (52.5%), estrogen-alone (32.4%), and progestogen-alone (15.1%). The median first-episode duration was 6.6 months; 38.8% of patients continued at 12 months. Black racial (adjusted hazard ratio [aHR] 1.52; 95% CI, 1.34–1.73) and Hispanic ethnic (aHR 1.43; 95% CI, 1.14–1.80) identities predicted faster discontinuation. Conversely, prior hysterectomy (aHR 0.75; 95% CI, 0.68–0.83) and concurrent local hormone use (aHR 0.84; 95% CI, 0.80–0.89) reduced discontinuation risk. CONCLUSION: Although one-fifth of women initiated systemic HT shortly after their diagnosis, low persistence and racial disparities among those who initiated reveal critical gaps in long-term menopause management. Furthermore, true real-world utilization is likely even lower due to underdocumentation in clinical coding. These findings underscore an urgent need for targeted, equitable interventions to improve treatment adherence and ensure consistent, comprehensive care for menopausal women.

  • Open Access

    Efficacy and safety of estrogen therapy for prevention of osteoporosis in postmenopausal women

    by Frank Z. Stanczyk, Sharon Winer, Intira Sriprasert, Adriana Wong, Donna Shoupe, Richard Paulson

    Multiple randomized controlled trials and observational studies have demonstrated that estrogens reduce the risk of osteoporotic-related fractures, including hip and vertebral and nonvertebral fractures, in postmenopausal women. However, many clinicians have concerns about adverse effects of estrogen, particularly those related to breast cancer and cardiovascular disease (CVD). The US Food and Drug Administration (FDA) was concerned about the negative impact that their “black box warning” was having on the use of estrogen products. In November 2025, the FDA removed the “black box warning” on estrogen products, arguing that in 30 trials with 26,708 women participants, menopausal hormone therapy (HT) was not associated with increased cancer mortality. In fact, women who start HT before age 60 appear to have a decreased mortality risk. The present manuscript discusses the biologic effects of estrogens on bone, and its efficacy and safety. Although it is generally accepted that knowing the circulating estradiol (E 2 ) concentration in a patient is not essential to initiate treatment for osteoporosis prevention, E 2 testing can still play an important role in the treatment process. A number of studies have reported threshold E 2 concentrations for preventing postmenopausal bone loss and osteoporosis. However, most studies that have reported these threshold concentrations utilized inaccurate E 2 assay methodology and, therefore, the conclusions are not valid. An accurate representation of the risk and benefits of estrogen therapy to women in menopausal transition and postmenopausal women is fundamental to improving their care, quality of life, and health.


  • Effect of hormone therapy on tryptophan metabolism and atherosclerosis among postmenopausal women

    by Intira Sriprasert, James R. Hilser, Naoko Kono, Roksana Karim, Frank Z. Stanczyk, Donna Shoupe, Howard N. Hodis, Wendy J. Mack, Hooman Allayee

    This study examined the effect of hormone therapy (HT) on tryptophan-kynurenine pathway metabolites and associations with atherosclerosis among postmenopausal women. Eighty early postmenopausal participants from the Early versus Late Intervention Trial with Estradiol (40 each from HT vs. placebo) were selected for analysis. Tryptophan, N-acetyltryptophan, kynurenine, kynurenic acid and N-acetylkynurenine baseline and 36-month levels were measured by mass spectrometry. Mixed models tested HT effects on each metabolite, association of estradiol (E2) level with change in metabolite levels and association between change of metabolite with carotid artery intima-media thickness (CIMT) progression. Compared with placebo, HT significantly reduced kynurenic acid (mean change HT minus placebo -0.27; 95% confidence interval [CI] - 0.42, -0.12; p = 0.0007) and N-acetylkynurenine (-0.38; 95% CI -0.68, -0.08; p = 0.04) levels. Reduction in kynurenic acid was inversely associated with higher E2 levels. Decreased CIMT progression was associated with lower kynurenic acid (0.0131 µm/year per unit; 95% CI 0.0049, 0.0212; p = 0.002) and N-acetylkynurenine (0.0061 µm/year per unit; 95% CI 0.0020, 0.0103; p = 0.004) levels. Plasma tryptophan-kynurenine pathway metabolites were reduced by HT and these reduced metabolite levels were associated with decreased atherosclerosis progression. Reduction of kynurenic acid by HT was supported by its association with E2 levels, which may explain, in part, the reduction in atherosclerosis progression with HT in early postmenopausal women.


  • Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women

    by Irene J Chen, Frank Z Stanczyk, Intira Sriprasert, Roksana Karim, Donna Shoupe, Naoko Kono, Howard N Hodis, Wendy J Mack

    Objective: The Early versus Late Intervention Trial with Estradiol demonstrated that hormone therapy (HT) reduces subclinical atherosclerosis progression in healthy postmenopausal women who initiated HT in proximity to menopause (<6 years) but not in those distant from menopause (≥10 years). This analysis explores the role of serum sex steroid hormones and sex hormone-binding globulin (SHBG) in atherosclerosis progression, examining differences based on time since menopause. Design: Post-trial analysis. Methods: The study included 535 healthy postmenopausal women; nearly half received HT. Serum levels of estradiol, estrone, testosterone, and SHBG were measured at baseline, 12 months, and 36 months. Carotid artery intima-media thickness (CIMT) was assessed every 6 months. Mixed-effects linear models evaluated the relationship between sex steroid hormones, SHBG, and CIMT progression, with time since menopause included as an interaction term, adjusting for age, hysterectomy, baseline CIMT, systolic blood pressure, and body mass index. Results: Late postmenopausal women were older with higher baseline CIMT. Associations between estradiol, estrone, and SHBG levels with CIMT progression differed significantly by time since menopause (interaction P < .01). In early postmenopause, CIMT progression was significantly inversely associated with SHBG (P = .024) and nonsignificantly inversely with estradiol and estrone. In late postmenopause, CIMT progression was significantly positively associated with estradiol (P = .005), estrone (P < .001), and SHBG (P = .037). Conclusions: Serum sex steroid hormones and SHBG relate differently to CIMT progression based on time since menopause. Estradiol, estrone, and SHBG levels show opposite associations with CIMT progression in early versus late postmenopause, highlighting the importance of HT timing in cardiovascular disease. Clinical trial registration number: ClinicalTrials.gov, NCT00114517.


  • Trends and comparisons of palliative care utilization for patients with metastatic gynecologic malignancy

    by Matthew W. Lee, Intira Sriprasert, Peter G. Phung, Christian Pino, Sabrina M. Woll, Andrew Vallejo, Katelyn B. Furey, Laila I. Muderspach, Lynda D. Roman, Jason D. Wright, et al.


  • Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women

    by Intira Sriprasert, Stephanie S Kim, Iram Elias Mohammed, Naoko Kono, Roksana Karim, Hooman Allayee, Howard N Hodis, Wendy J Mack, Ronald M Krauss

    Context The Early vs Late Intervention Trial with Estradiol (ELITE) showed that hormone therapy (HT) reduced atherosclerosis progression among early but not late postmenopausal women (PMW). Objective Determined by time-since-menopause (1) HT effects on lipids and lipoprotein particle subfractions (LPs), (2) associations of estradiol (E2) level with lipids and LPs, (3) associations of lipids and LPs with atherosclerosis progression. Design Randomized controlled trial stratified by time-since-menopause. Setting Academic institution. Participants Healthy postmenopausal women. Intervention Oral E2 with/without sequential vaginal progesterone. Main Outcome Measures Standard lipids and 21 LPs quantitated by ion mobility every 6 months. Results Among 562 PMW (240 early, 322 late), HT significantly increased total triglycerides (TG), high-density lipoprotein (HDL) cholesterol, small low-density lipoproteins (LDL), large HDL, and TG/C ratio in LDL and HDL and decreased LDL-cholesterol, total very low density lipoproteins (VLDL), small VLDL, intermediate-density lipoproteins, large LDL, and LDL peak diameter. HT showed no lipid or LP differences between time-since-menopause. Associations of E2 level with lipids and LPs explained the HT effects. Despite the nonsignificant P interaction by time-since-menopause, we observed that very small LDL and total HDL LPs were associated with atherosclerosis progression in late PMW. Conclusion HT effects on standard lipids and LPs are consistent with the literature. HT has similar effect on lipids and LPs in early and late PMW. Novel findings include discordant effects of HT on TG and VLDL particles, which can be explained by increased catabolism of atherogenic remnants of TG-rich lipoproteins. Our findings extend the well-known HT effects on standard lipids and LPs that may contribute to the beneficial effects on atherosclerosis progression in PMW.


  • Effect of menopausal hormone therapy on arterial wall echomorphology: Results from the Early versus Late Intervention Trial with Estradiol (ELITE)

    by Roksana Karim, Wenrui Xu, Naoko Kono, Intira Sriprasert, Yanjie Li, Mingzhu Yan, Frank Z. Stanczyk, Donna Shoupe, Wendy J. Mack, Howard N. Hodis


  • A Systematic Review and Meta-Analysis of Smoking and Circulating Sex Hormone Levels Among Premenopausal Women

    by Ugonna Ihenacho, Intira Sriprasert, Wendy J Mack, Ann S Hamilton, Jennifer B Unger, Michael F Press, Anna H Wu

    Introduction: It is established that higher prediagnostic circulating androgen and estrogen levels are associated with increased breast cancer risk in premenopausal and postmenopausal women. Pooled analyses in postmenopausal women report higher androgen and estrogen levels in current heavy cigarette smokers compared to nonsmokers. However, evidence among premenopausal women has been inconsistent. Aims and Methods: We conducted a systematic review and meta-analysis to estimate differences in standardized mean hormone levels among current premenopausal smokers compared to nonsmokers. We reviewed and collated publications with sex hormone levels by smoking status among healthy, premenopausal women who were nonusers of exogenous hormones, including oral contraceptives, using PubMed through December 2019. A random effects meta-analysis was conducted to combine the standardized mean differences (SMD) and 95% confidence intervals (CIs) for estradiol, progesterone, testosterone, dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and sex hormone-binding globulin by smoking status. Findings were summarized by menstrual cycle phase and overall. Results: Nineteen published peer-reviewed articles were included. Significantly increased testosterone levels among smokers compared to nonsmokers were identified from cross-sectional studies with varied menstrual phase timing (SMD 0.14; 95% CI 0.0005, 0.29) and significantly increased dehydroepiandrosterone-sulfate levels were found over all phases (SMD 0.12; 95% CI 0.01, 0.22). However, substantial heterogeneity existed in these studies. Conclusions: This meta-analysis suggests that smoking may increase blood androgen levels in healthy premenopausal women which may increase breast cancer risk; however, the differences were modest. Larger and covariate-adjusted studies with standardized collection over the menstrual cycle are needed to better understand this relationship and to reduce heterogeneity. Implications: Existing research has described associations between high prediagnostic estradiol and androgen levels with breast cancer risk among premenopausal women and has established active smoking as a breast cancer risk factor. However, the smoking and circulating sex hormone associations among premenopausal women remain inadequately studied. In this meta-analysis, we identified an association between smoking and higher mean testosterone and dehydroepiandrosterone-sulfate levels with consideration of menstrual phase, providing additional information on smoking’s potential pathway to premenopausal breast cancer.


  • Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women

    by Intira Sriprasert, Melissa Mert, Wendy J. Mack, Howard N. Hodis, Donna Shoupe